Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients
To evaluate the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer. Retrospective chart review. There were 194 patients with a diagnosis of uveal metastasis from lung cancer. Radiotherapy, chemotherapy, enucleation, or observation. Ocular tumor control, fi...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology (Rochester, Minn.) Minn.), 2014-01, Vol.121 (1), p.352-357 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 357 |
|---|---|
| container_issue | 1 |
| container_start_page | 352 |
| container_title | Ophthalmology (Rochester, Minn.) |
| container_volume | 121 |
| creator | Shah, Sanket U Mashayekhi, Arman Shields, Carol L Walia, Harpreet S Hubbard, 3rd, G Baker Zhang, Junjun Shields, Jerry A |
| description | To evaluate the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer.
Retrospective chart review.
There were 194 patients with a diagnosis of uveal metastasis from lung cancer.
Radiotherapy, chemotherapy, enucleation, or observation.
Ocular tumor control, final visual acuity, and tumor-related death.
There were 374 uveal metastatic tumors originating from primary lung cancer in 229 eyes of 194 patients. Tumor location included choroid (88%), ciliary body (2%), and iris (10%), with bilateral involvement in 18%. Diagnosis of uveal metastasis preceded the diagnosis of primary lung cancer in 44% of patients. The choroidal metastatic focus had a mean basal diameter of 8 mm and mean thickness of 3 mm, and were mostly located posterior to the equator (91%). The choroidal metastasis commonly had yellow or orange color (98%), had plateau (61%) or dome (38%) configuration, and displayed associated subretinal fluid (85%). Choroidal tumors were multifocal in 49 cases (23%). Ciliary body tumors were commonly dome shaped (75%) with an episcleral sentinel vessel (75%). Iris tumors were multifocal in 2 cases (13%), had visible intrinsic vessels (97%), and were associated with tumor seeding in the angle (38%) or on the iris stroma (25%). The uveal metastases were treated with teletherapy (31%), chemotherapy (18%), brachytherapy (9%), chemotherapy combined with teletherapy or brachytherapy (14%), enucleation (3%), or observation (21%). At last visit, eyes with follow-up showed tumor regression (66%), stability (12%), growth (14%), recurrence (3%), or new metastasis (5%). Visual acuity improved or remained stable in 59% eyes. One-year mortality from the time of detection of uveal metastasis was 54%.
Of 194 patients with uveal metastasis from lung cancer, 44% did not have a history of known lung cancer. Current methods of ocular treatment allow globe salvage in 92% of patients and improved/stable vision in 59% of patients. Systemic prognosis remains poor with tumor-related death in 54% of patients at 1 year. |
| doi_str_mv | 10.1016/j.ophtha.2013.07.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490765182</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490765182</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-495c011b492a0ef6dbec302b14544d53857df32bc9ca37392717e4a897f06b8d3</originalsourceid><addsrcrecordid>eNo1kE1LxDAYhIMg7rr6D0Ry9LCt75ukTeNNlvUDFry4N6Gk6Vu3S79sUsF_b8EVBmZgHuYwjN0gxAiY3h_jfjiEg40FoIxBx4DqjC0xUSZSGuWCXXp_BIA0leqCLYQ0WSYAluxj_0224S0F62fVnldj3_Jm6j65s52j8YG7pu5qN1MV2TCN5Nc8jHNsqQtrbruS91NwfUu87jgaxQcb6rnzV-y8so2n65Ov2P5p-755iXZvz6-bx100CMQQKZM4QCyUERaoSsuCnARRoEqUKhOZJbqspCiccVZqaYRGTcpmRleQFlkpV-zub3cY-6-JfMjb2jtqGttRP_kclQGdJpiJGb09oVPRUpkPY93a8Sf_f0T-ArUtYkM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490765182</pqid></control><display><type>article</type><title>Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Shah, Sanket U ; Mashayekhi, Arman ; Shields, Carol L ; Walia, Harpreet S ; Hubbard, 3rd, G Baker ; Zhang, Junjun ; Shields, Jerry A</creator><creatorcontrib>Shah, Sanket U ; Mashayekhi, Arman ; Shields, Carol L ; Walia, Harpreet S ; Hubbard, 3rd, G Baker ; Zhang, Junjun ; Shields, Jerry A</creatorcontrib><description>To evaluate the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer.
Retrospective chart review.
There were 194 patients with a diagnosis of uveal metastasis from lung cancer.
Radiotherapy, chemotherapy, enucleation, or observation.
Ocular tumor control, final visual acuity, and tumor-related death.
There were 374 uveal metastatic tumors originating from primary lung cancer in 229 eyes of 194 patients. Tumor location included choroid (88%), ciliary body (2%), and iris (10%), with bilateral involvement in 18%. Diagnosis of uveal metastasis preceded the diagnosis of primary lung cancer in 44% of patients. The choroidal metastatic focus had a mean basal diameter of 8 mm and mean thickness of 3 mm, and were mostly located posterior to the equator (91%). The choroidal metastasis commonly had yellow or orange color (98%), had plateau (61%) or dome (38%) configuration, and displayed associated subretinal fluid (85%). Choroidal tumors were multifocal in 49 cases (23%). Ciliary body tumors were commonly dome shaped (75%) with an episcleral sentinel vessel (75%). Iris tumors were multifocal in 2 cases (13%), had visible intrinsic vessels (97%), and were associated with tumor seeding in the angle (38%) or on the iris stroma (25%). The uveal metastases were treated with teletherapy (31%), chemotherapy (18%), brachytherapy (9%), chemotherapy combined with teletherapy or brachytherapy (14%), enucleation (3%), or observation (21%). At last visit, eyes with follow-up showed tumor regression (66%), stability (12%), growth (14%), recurrence (3%), or new metastasis (5%). Visual acuity improved or remained stable in 59% eyes. One-year mortality from the time of detection of uveal metastasis was 54%.
Of 194 patients with uveal metastasis from lung cancer, 44% did not have a history of known lung cancer. Current methods of ocular treatment allow globe salvage in 92% of patients and improved/stable vision in 59% of patients. Systemic prognosis remains poor with tumor-related death in 54% of patients at 1 year.</description><identifier>EISSN: 1549-4713</identifier><identifier>DOI: 10.1016/j.ophtha.2013.07.014</identifier><identifier>PMID: 23988200</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Brachytherapy ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Non-Small-Cell Lung - therapy ; Carcinoma, Small Cell - diagnosis ; Carcinoma, Small Cell - mortality ; Carcinoma, Small Cell - secondary ; Carcinoma, Small Cell - therapy ; Eye Enucleation ; Female ; Humans ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Uveal Neoplasms - diagnosis ; Uveal Neoplasms - mortality ; Uveal Neoplasms - secondary ; Uveal Neoplasms - therapy ; Visual Acuity</subject><ispartof>Ophthalmology (Rochester, Minn.), 2014-01, Vol.121 (1), p.352-357</ispartof><rights>Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23988200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shah, Sanket U</creatorcontrib><creatorcontrib>Mashayekhi, Arman</creatorcontrib><creatorcontrib>Shields, Carol L</creatorcontrib><creatorcontrib>Walia, Harpreet S</creatorcontrib><creatorcontrib>Hubbard, 3rd, G Baker</creatorcontrib><creatorcontrib>Zhang, Junjun</creatorcontrib><creatorcontrib>Shields, Jerry A</creatorcontrib><title>Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients</title><title>Ophthalmology (Rochester, Minn.)</title><addtitle>Ophthalmology</addtitle><description>To evaluate the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer.
Retrospective chart review.
There were 194 patients with a diagnosis of uveal metastasis from lung cancer.
Radiotherapy, chemotherapy, enucleation, or observation.
Ocular tumor control, final visual acuity, and tumor-related death.
There were 374 uveal metastatic tumors originating from primary lung cancer in 229 eyes of 194 patients. Tumor location included choroid (88%), ciliary body (2%), and iris (10%), with bilateral involvement in 18%. Diagnosis of uveal metastasis preceded the diagnosis of primary lung cancer in 44% of patients. The choroidal metastatic focus had a mean basal diameter of 8 mm and mean thickness of 3 mm, and were mostly located posterior to the equator (91%). The choroidal metastasis commonly had yellow or orange color (98%), had plateau (61%) or dome (38%) configuration, and displayed associated subretinal fluid (85%). Choroidal tumors were multifocal in 49 cases (23%). Ciliary body tumors were commonly dome shaped (75%) with an episcleral sentinel vessel (75%). Iris tumors were multifocal in 2 cases (13%), had visible intrinsic vessels (97%), and were associated with tumor seeding in the angle (38%) or on the iris stroma (25%). The uveal metastases were treated with teletherapy (31%), chemotherapy (18%), brachytherapy (9%), chemotherapy combined with teletherapy or brachytherapy (14%), enucleation (3%), or observation (21%). At last visit, eyes with follow-up showed tumor regression (66%), stability (12%), growth (14%), recurrence (3%), or new metastasis (5%). Visual acuity improved or remained stable in 59% eyes. One-year mortality from the time of detection of uveal metastasis was 54%.
Of 194 patients with uveal metastasis from lung cancer, 44% did not have a history of known lung cancer. Current methods of ocular treatment allow globe salvage in 92% of patients and improved/stable vision in 59% of patients. Systemic prognosis remains poor with tumor-related death in 54% of patients at 1 year.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Brachytherapy</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Carcinoma, Small Cell - diagnosis</subject><subject>Carcinoma, Small Cell - mortality</subject><subject>Carcinoma, Small Cell - secondary</subject><subject>Carcinoma, Small Cell - therapy</subject><subject>Eye Enucleation</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Uveal Neoplasms - diagnosis</subject><subject>Uveal Neoplasms - mortality</subject><subject>Uveal Neoplasms - secondary</subject><subject>Uveal Neoplasms - therapy</subject><subject>Visual Acuity</subject><issn>1549-4713</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LxDAYhIMg7rr6D0Ry9LCt75ukTeNNlvUDFry4N6Gk6Vu3S79sUsF_b8EVBmZgHuYwjN0gxAiY3h_jfjiEg40FoIxBx4DqjC0xUSZSGuWCXXp_BIA0leqCLYQ0WSYAluxj_0224S0F62fVnldj3_Jm6j65s52j8YG7pu5qN1MV2TCN5Nc8jHNsqQtrbruS91NwfUu87jgaxQcb6rnzV-y8so2n65Ov2P5p-755iXZvz6-bx100CMQQKZM4QCyUERaoSsuCnARRoEqUKhOZJbqspCiccVZqaYRGTcpmRleQFlkpV-zub3cY-6-JfMjb2jtqGttRP_kclQGdJpiJGb09oVPRUpkPY93a8Sf_f0T-ArUtYkM</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Shah, Sanket U</creator><creator>Mashayekhi, Arman</creator><creator>Shields, Carol L</creator><creator>Walia, Harpreet S</creator><creator>Hubbard, 3rd, G Baker</creator><creator>Zhang, Junjun</creator><creator>Shields, Jerry A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients</title><author>Shah, Sanket U ; Mashayekhi, Arman ; Shields, Carol L ; Walia, Harpreet S ; Hubbard, 3rd, G Baker ; Zhang, Junjun ; Shields, Jerry A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-495c011b492a0ef6dbec302b14544d53857df32bc9ca37392717e4a897f06b8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Brachytherapy</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Carcinoma, Small Cell - diagnosis</topic><topic>Carcinoma, Small Cell - mortality</topic><topic>Carcinoma, Small Cell - secondary</topic><topic>Carcinoma, Small Cell - therapy</topic><topic>Eye Enucleation</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Uveal Neoplasms - diagnosis</topic><topic>Uveal Neoplasms - mortality</topic><topic>Uveal Neoplasms - secondary</topic><topic>Uveal Neoplasms - therapy</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shah, Sanket U</creatorcontrib><creatorcontrib>Mashayekhi, Arman</creatorcontrib><creatorcontrib>Shields, Carol L</creatorcontrib><creatorcontrib>Walia, Harpreet S</creatorcontrib><creatorcontrib>Hubbard, 3rd, G Baker</creatorcontrib><creatorcontrib>Zhang, Junjun</creatorcontrib><creatorcontrib>Shields, Jerry A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Ophthalmology (Rochester, Minn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shah, Sanket U</au><au>Mashayekhi, Arman</au><au>Shields, Carol L</au><au>Walia, Harpreet S</au><au>Hubbard, 3rd, G Baker</au><au>Zhang, Junjun</au><au>Shields, Jerry A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients</atitle><jtitle>Ophthalmology (Rochester, Minn.)</jtitle><addtitle>Ophthalmology</addtitle><date>2014-01</date><risdate>2014</risdate><volume>121</volume><issue>1</issue><spage>352</spage><epage>357</epage><pages>352-357</pages><eissn>1549-4713</eissn><abstract>To evaluate the clinical features, treatment, and prognosis of patients with uveal metastasis from lung cancer.
Retrospective chart review.
There were 194 patients with a diagnosis of uveal metastasis from lung cancer.
Radiotherapy, chemotherapy, enucleation, or observation.
Ocular tumor control, final visual acuity, and tumor-related death.
There were 374 uveal metastatic tumors originating from primary lung cancer in 229 eyes of 194 patients. Tumor location included choroid (88%), ciliary body (2%), and iris (10%), with bilateral involvement in 18%. Diagnosis of uveal metastasis preceded the diagnosis of primary lung cancer in 44% of patients. The choroidal metastatic focus had a mean basal diameter of 8 mm and mean thickness of 3 mm, and were mostly located posterior to the equator (91%). The choroidal metastasis commonly had yellow or orange color (98%), had plateau (61%) or dome (38%) configuration, and displayed associated subretinal fluid (85%). Choroidal tumors were multifocal in 49 cases (23%). Ciliary body tumors were commonly dome shaped (75%) with an episcleral sentinel vessel (75%). Iris tumors were multifocal in 2 cases (13%), had visible intrinsic vessels (97%), and were associated with tumor seeding in the angle (38%) or on the iris stroma (25%). The uveal metastases were treated with teletherapy (31%), chemotherapy (18%), brachytherapy (9%), chemotherapy combined with teletherapy or brachytherapy (14%), enucleation (3%), or observation (21%). At last visit, eyes with follow-up showed tumor regression (66%), stability (12%), growth (14%), recurrence (3%), or new metastasis (5%). Visual acuity improved or remained stable in 59% eyes. One-year mortality from the time of detection of uveal metastasis was 54%.
Of 194 patients with uveal metastasis from lung cancer, 44% did not have a history of known lung cancer. Current methods of ocular treatment allow globe salvage in 92% of patients and improved/stable vision in 59% of patients. Systemic prognosis remains poor with tumor-related death in 54% of patients at 1 year.</abstract><cop>United States</cop><pmid>23988200</pmid><doi>10.1016/j.ophtha.2013.07.014</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1549-4713 |
| ispartof | Ophthalmology (Rochester, Minn.), 2014-01, Vol.121 (1), p.352-357 |
| issn | 1549-4713 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1490765182 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Brachytherapy Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Carcinoma, Non-Small-Cell Lung - therapy Carcinoma, Small Cell - diagnosis Carcinoma, Small Cell - mortality Carcinoma, Small Cell - secondary Carcinoma, Small Cell - therapy Eye Enucleation Female Humans Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged Retrospective Studies Survival Rate Treatment Outcome Uveal Neoplasms - diagnosis Uveal Neoplasms - mortality Uveal Neoplasms - secondary Uveal Neoplasms - therapy Visual Acuity |
| title | Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T22%3A37%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Uveal%20metastasis%20from%20lung%20cancer:%20clinical%20features,%20treatment,%20and%20outcome%20in%20194%20patients&rft.jtitle=Ophthalmology%20(Rochester,%20Minn.)&rft.au=Shah,%20Sanket%20U&rft.date=2014-01&rft.volume=121&rft.issue=1&rft.spage=352&rft.epage=357&rft.pages=352-357&rft.eissn=1549-4713&rft_id=info:doi/10.1016/j.ophtha.2013.07.014&rft_dat=%3Cproquest_pubme%3E1490765182%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490765182&rft_id=info:pmid/23988200&rfr_iscdi=true |